A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105

RET fusions are oncogenic drivers of various tumors, including non-small cell lung cancers (NSCLCs). The safety and antitumor activity of the multikinase RET inhibitor RXDX-105 were explored in a phase I/Ib trial. A recommended phase 2 dose of 275 mg fed daily was identified. The most common treatme...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Drilon, Alexander, Fu, Siqing, Patel, Manish R., Fakih, Marwan, Wang, Ding, Olszanski, Anthony J., Morgensztern, Daniel, Liu, Stephen V., Cho, Byoung Chul, Bazhenova, Lyudmila, Rodriguez, Cristina P., Doebele, Robert C., Wozniak, Antoinette, Reckamp, Karen L., Seery, Tara, Nikolinakos, Petros, Hu, Zheyi, Oliver, Jennifer W., Trone, Denise, McArthur, Katherine, Patel, Rupal, Multani, Pratik S., Ahn, Myung-Ju
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6397691/
https://ncbi.nlm.nih.gov/pubmed/30487236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-18-0839
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados